AnaptysBio (ANAB) Projected to Post Earnings on Tuesday

AnaptysBio (NASDAQ:ANAB) is anticipated to release its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect AnaptysBio to post earnings of ($1.32) per share and revenue of $15.8260 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 3:00 PM ET.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The company had revenue of $22.26 million during the quarter, compared to analysts’ expectations of $11.55 million. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Price Performance

ANAB stock opened at $36.58 on Friday. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $38.38. The company has a 50-day moving average of $27.14 and a two-hundred day moving average of $24.13. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -8.17 and a beta of -0.18.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its position in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Osaic Holdings Inc. raised its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter. Creative Planning raised its position in AnaptysBio by 26.9% in the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock worth $374,000 after purchasing an additional 3,571 shares in the last quarter. Brevan Howard Capital Management LP raised its position in AnaptysBio by 61.7% in the second quarter. Brevan Howard Capital Management LP now owns 22,953 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 8,761 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock worth $558,000 after purchasing an additional 18,165 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have issued reports on ANAB. UBS Group restated a “neutral” rating and set a $20.00 price target (up from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Wedbush upped their price target on shares of AnaptysBio from $45.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Stifel Nicolaus increased their target price on shares of AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and an average target price of $57.30.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.